Advancing Innovations for Diabetes and Cardiovascular Disease with Lexicon Pharmaceuticals’ CEO Mike Exton

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks.com, welcomes Mike Exton, PhD, CEO of Lexicon Pharmaceuticals, for a conversation about leveraging gene science to develop innovative medicines for serious chronic conditions. Dr. Exton discusses Lexicon’s growing pipeline, which includes promising therapies for diabetic peripheral neuropathic pain, hypertrophic cardiomyopathy and other cardiometabolic diseases, areas where unmet need remains high despite decades of research. He also shares insights from his extensive leadership experience across the pharmaceutical industry, including his time as Cardiometabolism Therapeutic Head at Novartis, and how those experiences are shaping his vision for Lexicon’s next chapter of growth. Prior to joining Novartis, Dr. Exton was director of business development with Invida Pty Ltd and spent nine years with Eli Lilly Australia, where he held a variety of research, business development and sales positions. Dr. Exton has served as CEO and a director at Lexicon Pharmaceuticals since July 2024. Dr. Exton has a BSc and a PhD in neuroscience from the University of Newcastle and a PhD in immunology from the University of Essen, Germany. Tune in to hear how Lexicon is advancing precision-driven approaches to transform treatment outcomes in diabetes, pain management and heart disease, and how gene science continues to redefine possibilities in chronic disease therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured